Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 2, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Respiratory, Dermatology, Musculoskeletal Disorders, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Metabolic Disorders and Oncology which include indications Idiopathic Pulmonary Fibrosis, Fibrosis, Neuropathic Pain (Neuralgia), Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Skin Inflammation and Wounds.

The latest report Type 2 Angiotensin II Receptor – Drugs In Development, 2022, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

– The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

Reasons to Buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Confo Therapeutics SA
HK inno.N Corp
MorphoSys AG
Novopyxis Inc
Shandong Danhong Pharmaceutical Co Ltd
Vicore Pharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Overview

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Companies Involved in Therapeutics Development

Confo Therapeutics SA

HK inno.N Corp

MorphoSys AG

Novopyxis Inc

Shandong Danhong Pharmaceutical Co Ltd

Vicore Pharma AB

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Drug Profiles

(amlodipine besylate + valsartan) + atorvastatin calcium – Drug Profile

Product Description

Mechanism Of Action

History of Events

C-106 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CFTX-1554 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MOR-107 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NP-6A – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis – Drug Profile

Product Description

Mechanism Of Action

thalidomide – Drug Profile

Product Description

Mechanism Of Action

History of Events

VP-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VP-03 – Drug Profile

Product Description

Mechanism Of Action

History of Events

WXSH-0024 – Drug Profile

Product Description

Mechanism Of Action

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Dormant Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Discontinued Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Product Development Milestones

Featured News & Press Releases

Jun 28, 2022: Confo Therapeutics awarded EUR

1.7M VLAIO grant to expand application of ConfoBody drug discovery and development technology in rare diseases

Jun 17, 2022: Vicore Pharma starts Phase I trial of angiotensin II type 2 receptor agonist

Jun 03, 2022: Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients

Mar 18, 2022: Vicore initiates human forearm blood flow study with C21

Mar 10, 2022: Confo Therapeutics doses first subjects in phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain

Mar 10, 2022: Confo Therapeutics doses first subjects in phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain

Mar 09, 2022: Vicore strengthens rare lung disease pipeline with PAH indication

Mar 04, 2022: Vicore to host R&D-Day

Mar 04, 2022: Vicore to host R&D Day

Feb 10, 2022: Vicore's AIR study interim analysis suggests that C21 improves lung function in IPF patients

Dec 15, 2021: Confo Therapeutics expands patent estate for ConfoBody-based GPCR screening platform

Nov 02, 2021: Vicore's C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study

Oct 25, 2021: Vicore Pharma Holding: Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19

Sep 22, 2021: Vicore to host Key Opinion Leader webinar on C21 for the treatment of idiopathic pulmonary fibrosis (IPF)

Sep 22, 2021: Vicore obtains SARS coronavirus patent for C21 in the USA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Confo Therapeutics SA, 2022

Pipeline by HK inno.N Corp, 2022

Pipeline by MorphoSys AG, 2022

Pipeline by Novopyxis Inc, 2022

Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022

Pipeline by Vicore Pharma AB, 2022

Dormant Projects, 2022

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.